Local prostaglandin E2 in patients with oral malignancies undergoing chemo- and radiotherapy.
Patients undergoing chemo- and/or radiotherapy for malignancies were often found to develop annoying inflammation of the oral mucosa. As prostaglandins are known to be cytoprotective. Prostaglandin E2 was given to 10 patients who received combined radio- and chemotherapy for oral neoplasms. Patients receiving PGE2 reported substantially less intense pain then those in the control group. Our statistically significant results indicate that topical treatment of side effects produced by combined radio- and chemotherapy of oral neoplasms with PGE2 holds promise and is clearly superior to conventional treatment modalities.
Porteder
H
H
Dept. of Maxillo-Facial Surgery, University of Vienna, Austria.
Rausch
E
E
Kment
G
G
Watzek
G
G
Matejka
M
M
Sinzinger
H
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy; D003131:Combined Modality Therapy; D015232:Dinoprostone / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D013280:Stomatitis / Q000139:chemically induced / Q000188:drug therapy* / Q000209:etiology
D000970:Antineoplastic Agents; D015232:Dinoprostone